Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Arthritis, Rheumatoid 2Stroke 1Spondylitis, Ankylosing 1Pulmonary Disease, Chronic Obstructive 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Kidney Failure, Chronic 1Diabetes Mellitus 1Coronary Artery Disease 1COVID-19 1

Interventions

Methotrexate 4Abatacept 3tocilizumab 2olokizumab 2Rituximab 2tofacitinib 1secukinumab 1golimumab 1baricitinib 1Radioimmunodetection 1RC-18 1Etanercept 1Double-Blind Method 1Certolizumab Pegol 1Antirheumatic Agents 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Arthritis, Rheumatoid × tocilizumab × Clear all
NCT02046603 2018-12-07

ACT-MOVE

Hoffmann-La Roche

Phase 3 Completed
162 enrolled 30 charts

Arthritis, Rheumatoid

NCT00883753 2014-08-06

An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy

Hoffmann-La Roche

Phase 3 Completed
934 enrolled 40 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡